Experienced in Familial Hypertriglyceridemia

Xiuwen J. Wang

107 Wenhuaxi Road, 
Jinan, CN 
Experienced in Familial Hypertriglyceridemia
107 Wenhuaxi Road, 
Jinan, CN 
OverviewLocationsClinical Research

Overview

Xiuwen Wang practices in Jinan, China. Wang is rated as an Experienced expert by MediFind in the treatment of Familial Hypertriglyceridemia. Their top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Synovial Sarcoma, and Candida Infection of the Skin.

Their clinical research consists of co-authoring 106 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Familial Hypertriglyceridemia.

Locations

107 Wenhuaxi Road, Jinan, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) (Anti-PD1 Antibody) Combined With Platinum-Pemetrexed Versus Platinum-Pemetrexed Alone as First-line Treatment for Patients With Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer
A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) (Anti-PD1 Antibody) Combined With Platinum-Pemetrexed Versus Platinum-Pemetrexed Alone as First-line Treatment for Patients With Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drugs: Tislelizumab+Cisplatin or Carboplatin+Pemetrexed, Cisplatin or Carboplatin+Pemetrexed
Study Phase: Phase 3

106 Total Publications

What is the optimal first-line regimen for patients with advanced HER2-positive breast cancer: A systematic review and network meta-analysis.
What is the optimal first-line regimen for patients with advanced HER2-positive breast cancer: A systematic review and network meta-analysis.
Journal: Journal of cancer research and therapeutics
Published: January 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wang's expertise for a condition
ConditionClose
      View All 27 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile